China's National Medical Products Administration (NMPA) approved Innovent and Eli Lilly's GLP-1R/GCGR dual agonist mazdutide for chronic weight management in adults with obesity or overweight. The oxyntomodulin analogue demonstrated superior weight loss (up to −14.84% at 48 weeks) and metabolic benefits in the Phase III GLORY-1 trial (n=610), while improving liver fat content by −80.24% in patients with baseline hepatic steatosis ≥10%.

Mazdutide's new drug application for type 2 diabetes (T2D) is under review in China. Seven Phase III trials are ongoing, including head-to-head studies against semaglutide and dulaglutide. The therapy showed a safety profile consistent with GLP-1 receptor agonists, with predominantly mild-to-moderate gastrointestinal adverse events. Additional Phase III trials are planned for metabolic dysfunction-associated steatohepatitis (MASH) and adolescent obesity.